Galectin Therapeutics Inc. (NASDAQ:GALT) – Research analysts at Roth Capital increased their Q1 2017 earnings estimates for shares of Galectin Therapeutics in a report released on Wednesday. Roth Capital analyst S. Yaniv now forecasts that the brokerage will post earnings per share of ($0.15) for the quarter, up from their prior estimate of ($0.17). Roth Capital currently has a “Sell” rating and a $0.75 target price on the stock. Roth Capital also issued estimates for Galectin Therapeutics’ Q2 2017 earnings at ($0.16) EPS, Q3 2017 earnings at ($0.12) EPS, Q4 2017 earnings at ($0.09) EPS, FY2017 earnings at ($0.51) EPS, FY2018 earnings at ($0.18) EPS, FY2019 earnings at ($0.20) EPS and FY2020 earnings at ($0.19) EPS.
Other research analysts also recently issued research reports about the company. FBR & Co restated a “buy” rating on shares of Galectin Therapeutics in a research note on Friday, August 26th. HC Wainwright restated a “buy” rating on shares of Galectin Therapeutics in a research note on Tuesday, August 16th. Finally, Zacks Investment Research upgraded Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a research note on Monday, August 15th.
Galectin Therapeutics (NASDAQ:GALT) traded down 7.705% on Friday, reaching $1.126. The company had a trading volume of 1,208,821 shares. Galectin Therapeutics has a 12-month low of $1.08 and a 12-month high of $3.25. The stock’s 50-day moving average price is $1.88 and its 200-day moving average price is $1.60. The stock’s market capitalization is $32.97 million.
Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.20) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.04.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Fund Advisors increased its position in Galectin Therapeutics by 33.8% in the second quarter. BlackRock Fund Advisors now owns 78,955 shares of the company’s stock valued at $116,000 after buying an additional 19,967 shares during the last quarter. Advisor Group Inc. purchased a new position in Galectin Therapeutics during the second quarter valued at $584,000. Finally, Vanguard Group Inc. increased its position in Galectin Therapeutics by 0.4% in the second quarter. Vanguard Group Inc. now owns 606,537 shares of the company’s stock valued at $892,000 after buying an additional 2,490 shares during the last quarter. Institutional investors own 11.69% of the company’s stock.
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.